Please login to the form below

Not currently logged in
Email:
Password:

Summit appoints Pfizer/Bayer veteran as CMO

David Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile

Summit David RoblinIndustry veteran Dr David Roblin has joined the Oxford, UK-based drug development and discovery company Summit as its chief medical officer.

Dr Roblin has years of senior research experience at major pharma firms, including serving as head of research, site director and chief medical officer for Europe R&D during a spell with Pfizer.

He was also head of ant-infectives at Bayer, where he led the development of several antiobiotics, including Avelox (moxifloxacin) and Cipro (ciprofloxacin).

This experience in anti-infectives will prove useful at Summit, with the company's research efforts including the development of treatments for C difficile infection in addition to potential thereapies for Duchenne muscular dystrophy.

"David brings considerable expertise in all aspects of drug development having been instrumental in the successful development of a number of important medicines,” said Summit's CEO Glyn Edwards.

“As our Duchenne muscular dystrophy and C difficile infection drug programmes go through patient clinical trials, David will make a major contribution to their successful development."

13th June 2013

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....
Main image1
Global leaders in digital channels
Exploring why UK field teams are global leaders in digital channels is key to better understanding the changes in omnichannel engagement...
Kate Shaw reflects on Innovative Trials' first US office openings
On Thanksgiving, Kate Shaw, Founder and CEO of Innovative Trials, reflects on the company first US office opening...